leisure time -WSS

leisure time

author：focus 2025-10-06 13:45:36 Page View：76477

Editor’s note: A recording of the event is embedded below.

Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

Let’s dive in and discuss what to watch in the months ahead.

Speakers:

Alex Brill, CEO, Matrix Global Advisors
Chris Brown, managing partner and co-founder, Integrity Rx Partners
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Thomas Newcomer, head of U.S. market access, Samsung Bioepis (sponsor speaker)

Previous article： A controversial new treatment promises to make little people taller
Next article： Hollywood unions extend contract negotiations for actors

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

CDC recommends RSV monoclonal antibody for infants

Beyfortus,anewRSVmonoclonalantibodySanofiApanelofadviserstotheCentersforDiseaseControlandPreventionu

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

'Null' research findings aren't empty of meaning. Let's publish them

APStockEverymedicalresearcherdreamsofdoingstudiesorconductingclinicaltrialsthatgenerateresultssocomp